Pacira BioSciences, Inc.

Pacira BioSciences, Inc. is a healthcare company focused on developing, manufacturing, marketing, distributing, and selling non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. Its primary product is EXPAREL, a bupivacaine liposome injectable suspension used for postsurgical pain management. The company also offers ZILRETTA, an extended-release injectable suspension for osteoarthritis knee pain, and the iovera system, a non-opioid handheld cryoanalgesia device that delivers controlled cold to targeted nerves to block pain signals. Additionally, Pacira is developing PCRX-201, a gene therapy vector platform for local administration of genetic medicines to treat prevalent diseases like osteoarthritis. Through a partnership with Aratana Therapeutics, it also supplies NOCITA, a bupivacaine liposome product for veterinary use.

Pacira BioSciences is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PCRX. Its financial reporting and stock trading are conducted in US Dollars (USD), as the company is headquartered in the United States. The exchange is one of the major US stock exchanges, providing liquidity and visibility for investors. The company's primary operations and revenue are generated in the US, and its stock is traded in USD, making it accessible to domestic and international investors through US-based brokerage accounts.

Pacira BioSciences operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification reflects its focus on developing and manufacturing specialized pharmaceutical products, particularly non-opioid pain management and regenerative health solutions. As a specialty drug manufacturer, Pacira targets specific therapeutic areas such as postsurgical pain and osteoarthritis, differentiating itself from broad-based generic drug companies. Its products like EXPAREL and ZILRETTA are proprietary formulations that address unmet medical needs in pain management, aligning with the specialty pharmaceutical segment.

Pacira BioSciences is headquartered in Brisbane, California, United States. The company primarily serves the US healthcare market, providing its non-opioid pain management and regenerative health solutions to healthcare practitioners across the country. Its products are marketed and distributed domestically, with no mention of international operations in the available data. The company was originally incorporated in 2006 as Pacira Pharmaceuticals, Inc. and rebranded to Pacira BioSciences in April 2019. The headquarters location in California places it within a major biotechnology and pharmaceutical hub, supporting its research, development, and commercial activities.

Pacira BioSciences' portfolio includes several key products for pain management and regenerative health. EXPAREL is a bupivacaine liposome injectable suspension used for postsurgical pain management, designed to provide prolonged analgesia. ZILRETTA is a triamcinolone acetonide extended-release injectable suspension indicated for managing osteoarthritis knee pain. The iovera system is a non-opioid handheld cryoanalgesia device that delivers controlled cold temperatures to targeted nerves, creating a neurolytic block to interrupt pain signals. Additionally, the company is developing PCRX-201, a novel gene therapy vector platform for local administration of genetic medicines to treat large prevalent diseases like osteoarthritis. Through a partnership with Aratana Therapeutics, Pacira also supplies NOCITA, a bupivacaine liposome product for veterinary use.